

OTO6 Rec'd PCT/PTO 2 2 OCT 2002

POT

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: P. York et al.)	Atty Docket No.: 0113.00
)	Examiner: Unassigned
Application No. 10/070,093)	Group Art Unit: Unknown
Filed: February 27, 2002)	October 3, 2002
Title: CONFORMULATION METHODS AND THEIR PRODUCTS))	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on // OCT O2

Signed: Minno Cotter

UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents Washington, DC 20231

Dear Sir:

The references listed in the attached Form PTO/SB/08A,B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

Copies of the references are enclosed, as required under 37 CFR §\$1.98.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in section 1.491 in an international

application event occurs la	perfore the mailing date of a first Office actual on the merits (whichever int);
of a first Office	
	the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00); or
	one of the following statements as specified in 37 CFR 1.97(e) that:
	each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
	no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement; or
after the mail	ng date of either a final action under section 1.113 or a notice of
	er section 1.311, but on or before the payment of the issue fee, and is
accompanied	
	the following petition: Applicant hereby requests consideration of the accompanying information disclosure statement;
	the petition fee set forth in 37 CFR 1.17(i) (\$130.00); and
	one of the following statements as specified in 37 CFR 1.97(e) that: each item of information contained in the information disclosure
	statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
	no item of information contained in the information disclosure statement was cited in a communication from a foreign patent

office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement.

	Each item of information contained within this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. Accordingly, this Information Disclosure Statement does not constitute a failure on the part of the Applicant to engage in reasonable efforts to conclude prosecution of the application as set forth in 37 CFR 1.704 "Reduction of period of adjustment of patent term."
	Attached is Check No in the amount of <u>\$0</u> .
	Please charge the amount of \$ to Deposit Account 500348
\boxtimes	If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 50-0348.
	Respectfully submitted,
	INHALE THERAPEUTIC SYSTEMS, INC.
Dated	By: Michael J. Rafa Reg. No. 38,740

San Carlos, CA 94070 (650) 631-3100



PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/070.093 INFORMATION DISCLOSURE 02/27/2002 Filing Date STATEMENT BY APPLICANT First Named Inventor P. York et al Art Unit (use as many sheets as necessary) Unassigned Examiner Name Attorney Docket Number 0113.00 of Sheet

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*		Document Number Number - Kind Code ² (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-4,328.107	05/04/1982	Wright	
	AB	US-4,361,285	11/30/1982	Koppehele et al.	
	AC	US-4,582.731	04/15/1986	Smith	
	AD	US-4,702.799	10/27/1987	Tuot	
	AE	US-4,737,384	04/12/1988	Murthy et al.	
	AF	US- 4.919.853	04/24/1990	Alvarez et al.	<u> </u>
	AG	US- 4,923,720	05/08/1990	Lee et al.	
	AH	US-4.970.093	11/13/1990	Sievers et al.	
	ΑI	US-4,977.785	12/18/1990	Willoughby et al.	
	AJ	US- 5,009,367	04/23/1991	Nielsen	
	AK	US- 5,043,280	08/27/1991	Fischer et al.	
	AL	US-5.106,659	04/21/1992	Hastings et al.	
	AM	US-5,221,731	06/22/1993	Weymans et al.	<u> </u>
	AN		07/20/1993	Paul et al.	
	AO	US- 5.437.798	08/01/1995	LaRoche et al.	
	AP	US- 5,548,004	08/20/1996	Mandel et al.	
	AQ	US- 5,554,382	09/10/1996	Castor	
	AR	US- 5,639,441	06/17/1997	Sievers et al.	
_	AS		01/13/1998	Schmitt	
	AT	US- 5.708.039	01/13/1998	Daly et al.	

			FOREIGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (6)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
	AX		06/25/1992	Schwarz Pharma AG		ļ
	AY		03/24/1960	F. Aktiengesellschaft		<u> </u>
	AZ		05/05/1993	W. Fischer		$oxed{oxed}$
	BA	EP 0542314	05/19/1993	P. Debenedetti		↓
	BB	JP 1-176437	07/12/1989	T. Tauchi		<u> </u>
	BC	JP 5-57166	03/09/1993	K. Kitagawa		┞
	BD	WO 90/11139	10/04/1990	K. Nielsen	<u> </u>	_
	+	WO 90/03782	04/19/1990	W. Schmitt		_
	CP	GB 2322326	08/26/1998	Bradford Particle		↓_
	_	WO 95/21688	08/17/1995	W. Eckhard et al.		

Examiner	Date	1
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English page 12 attached. English language Translation is attached.



PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitut	e for form 1449A/P	то		Complete if Known			
				Application Number	10/070.093		
INFO	PRMATIO	N DI	SCLOSURE	Filing Date	02/27/2002		
STA	TEMENT	BY A	APPLICANT	First Named Inventor	P. York et al.		
				Art Unit			
	(use as many sl	heets a	s necessary)	Examiner Name	Unassigned		
Sheet	2	of	6	Attorney Docket Numbe	10113.00		

	•		U.S. PAT	ENT DOCUMENTS	
Examiner Initials*		Document Number Number - Kind Code ² (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AU	US-5.716.558	02/10/1998	Nielsen et al.	
	ΑV	US-5.981.474	11/09/1999	Manning et al.	
	AW	US-6.063,910	05/16/2000	Debenedetti et al.	
		US-			
	<u> </u>	US-			
		US-			
	i	US-			
		US-			
		US-			
		US-			

		FORI	IGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code3 -Number ⁴ -Kind Code ⁵ (#known)		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
	CR	WO 95/01221	01/12/1995	Univ. Bradford		
	CS	WO 96/00610	01/11/1996	Univ. Bradford		
						\vdash
!	<u> </u>					\vdash
-	-					├
						\vdash
	-					\vdash
						\vdash

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

EXAMINEH: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Outration to de	Substitute for form 1449B/PTO NFORMATION DISCLOSURE		Complete if Known		
			Application Number	10/070.093	
INFO	RMATION	DIS	CLOSURE	Filing Date	02/27/2002
STATEMENT BY APPLICANT				First Named Inventor	P. York et al.
SIAI	CINICIAI D	. ^	FILIOAN	Group Art Unit	
	(use as many sh	eets a	s necessary)	Examiner Name	Unassigned
Sheet	3	of	6	Attorney Docket Number	0113.00

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	T
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	BF	DEBENEDETTI ET AL., "Application of Supercritical Fluids for the Production of Sustained Delivery Devices," J. Cont. Rel, No. 24, p. 27-44 (1993).	
	BG	DIXON ET AL., "Polymeric Materials Formed by Precipitation with a Compressed Fluid Antisolvent." A1ChE J., Vol. 39 (No. 1), p. 127-139 (1993).	
	вн	TOM ET AL., "Applications of Supercritical Fluids in the Controlled Release of Drugs," ACS Symposium Series, Supercritical Fluid Engineering Science Fundamentals and Applications, Chpt. 19, p. 238-257 (1993).	
	BI	LARSON ET AL., "Evaluation of Supercritical Fluid Extraction in the Pharmaceutical Industry." Biotech. Progress, Vol. 2 (No. 2), p. 73-82 (1986).	
	ВЈ	Ullmans Encyclopedia of Industrial Chemistry, Vol. B2, Fifth Ed., title page, copyright page, and p. 7-21 and 7-22 (1988).	
	BK	TOM ET AL., "Particle Formation with Supercritical Fluids - A Review," J. Aerosol Sci., 1st Ed. Vol. 22 (No. 5), p. 555-584 (1981).	
	BL	DEBENEDETTI ET AL., "Rapid Expansion of Supercritical Solutions (RESS): Fundamentals and Applications," Fluid Phase Equilibria, Vol. 82, p. 311-321 (1993).	
	ВМ	GALLAGHER ET AL., "Gas AntiSolvent Recrystallization: New Process to Recrystallize Compounds Insoluble in Supercritical Fluids," ACS Symp. Ser No. 406, p. 334-354 (1989)	
	BN	LAHIERE ET AL., "Mass-Transfer Efficiencies of Column Contactors in Supercritical Extraction Service," Ind. Eng. Chem. Res. No. 26. p. 2086-2092 (1987)	
	ВО	STAHL ET AL., "Dense Gas Extraction on a Laboratory Scale: A Survey of Some Recent Results." Fluid Phase Equilibria, No. 10, p. 269-278 (1983).	
	BP	DILL ET AL., "Denatured States of Proteins," Annu. Rev. Biochem, No. 60, p. 795-825 (1991).	

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

	(1.140B/DTO			Complete if Known		
	or form 1449B/PTO RMATION		CLOSURE		10/070.093 02/27/2002	
STAT	EMENT E	BY A	PPLICANT	First Named Inventor Group Art Unit	P. York et al.	
	(use as many s	sheets a	s necessary)	Examiner Name	Unassigned	
Sheet	4	of	6	Attorney Docket Number	0113.00	

-		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	-
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ
	BQ	O'CALLAGHAN ET AL., "Novel Method for Detection of (B)-Lactamases by Using a Chromogenic Cephalosporin Substrate," Antimicrobial Agents and Chemotherapy, Vol. 1 (No. 4), p. 283-288 (1972).	
	BR	JUNG ET AL., "Particle Design Using Supercritical Fluids: Literature and Patent Survey." J. of Supercritical Fulids, Vol. 20, p. 179-219 (2001).	
		BLEICH ET AL., "Aerosol Solvent Extraction System - A New Microparticle Production Technique," International J. of Pharmaceutics, Vol. 97, p. 111-117 (1993).	
	ВТ	CHANG ET AL, "Separation of B-Carotene Mixtures Precipitated from Liquid Solvents with High-Pressure CO2," Biotechnol. Prog., No. 7, p. 275-278 (1991).	_
	BU	GALLAGHER ET AL., "Gas Anti-Solvent Recrystallization of RDX: Formation of Ultra-fine Particles of a Difficult-to-Comminute Explosive," The J. of Supercritical Fluids, No. 5, p. 130-142 (1992).	
	BV	MATSON ET AL., "Production of Powders and Films by the Rapid Expansion of Supercritical Solutions." J. of Materials Science, No. 22, p. 1919-1928 (1987).	
	BW	MOHAMED ET AL., "Solids Formation After the Expansion of Supercritical Mixtures," Supercritical Fluid Science and Technology, Chapter 23, American Chemical Society, p. 355-378 (1989).	
	BX	BARJ ET AL, "Submicronic MgAI2O4 Powder Synthesis in Supercritical Ethanol," J. of Materials Sci., No. 27, p. 2187-2192 (1992).	
	BY	CHHOR ET AL., "Synthesis of Submicron TIO2 Powders in Vapor, Liquid and Supercritical Phases, a Comparative Study," Materials Chemistry and Physics, Vol. 32, p. 249-254 (1992).	ı
	BZ	FRANCIS, "Ternary Systems of Liquid Carbon Dioxide," J. of Physical Chemistry, Vol. 58, p. 1099-1114 (1954).	
	CA	YEO ET AL., "Formation of Microparticulate Protein Powders Using a Supercritical Fluid Antisolvent," Biotechnology and Bioengineering, Vol. 41, p. 341-346 (1993).	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Out attended to	- 40 4.440B/BTO			Complete if Known			
	r form 1449B/PTO		01 001105	Application Number	10/070.093		
INFOF	RMATION [SIC	CLOSURE	Filing Date	02/27/2002		
CTAT	EMENIT RV	Δ	PPLICANT	First Named Inventor	P. York et al.		
SIAII	CIAICIAI DI	^	FFLIOAII	Group Art Unit			
	(use as many she	ets a	s necessary)	Examiner Name	Unassigned		
Sheet	5	of	6	Attorney Docket Number	0113.00		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	СВ	RANDOLPH ET AL., "Sub-Micrometer-Sized Biodegradable Particles of Poly (L-Lactic Acid) via the Gas Antisolvent Spray Precipitation Process," Biotechnol. Prog, Vol. 9, No. 4, p. 429-435 (1993).	_
	CC	DEBENEDETTI ET AL., "Supercritical Fluids: A New Medium for the Formation of Particles of Biomedical Interest," Proceed. Intern. Symp. Control Rel. Bioact. Mater., 20, p. 141-142 (1993).	
	CD	DONSI ET AL., "Micronization by Means of Supercritical Fluids: Possibility of Application to Pharmaceutical Field." Pharm. ACTA HELV. 66, Nr. 5-6, p. 170-173 (1991).	
	CE	CYGNAROWICZ ET AL., "Design and Control of a Process to Extract B-Carotene with Supercritical Carbon Dioxide," Biotechnol. Prog. Vol. 6, p. 82-91 (1990).	
	CF	CHEN ET AL., "Supercritical Antisolvnet Fractionation of Polyethylene Simulated with Multistage Algorithm and SAFTEquation of State: Staging Leads to High Selectivity Enhacements for Light Fractions," Ind. Eng. Chem. Res., Vol. 33, p. 306-310 (1994).	
		LOTH ET AL., "Properites and Dissolution of Drugs Micronized by Crystallization from Supercritical Gases." International J. of Pharmaceuticals, Vol. 32, p. 265-267 (1986).	
	СН	BODMEIER ET AL., "Polymeric Microspheres Prepared by Spraying Into Compressed Carbon Dioxide," Pharmaceutical Research, Vol. 12, No. 8, p. 1211-1217 (1995).	
	CI	TOM ET AL., "Formation of Bioerodible Polymeric Microspheres and Microparticles by Rapid Expansion of Supercritical Solutions," Biotechnol. Prog., Vol. 7, p. 403-411 (1991).	
	C1	SANCHEZ ET AL., "Development of Biodegradable Microspheres and Nanospheres for the Controlled Release of Cyclosporin A." International J. of Pharmaceutics, Vol. 99, p. 263-273 (1993).	
	CK	JULIENNE ET AL., "Preparation of Poly (D, L-Lactide/Glycolide) Nanoparticles of Controlled Particle Size Distribution: Application of Experimental Designs," Drug Development and Industrial Pharmacy, Vol. 18, No. 10, p. 1063-1077 (1992).	s
	CL	PHILLIPS ET AL, "Rapid Expansion from Supercritical Solutions: Application to Pharmaceutical Processes," International J. of Pharmaceutics, Vol. 94, p. 1-10 (1993).	

Examiner	Date	
Signature	Considered	_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
_	r form 1449B/PTO			Application Number	10/070.093	
INFOF	RMATION I	DIS	CLOSURE		02/27/2002	
CTAT	EMENT BY	/ AE	PPLICANT	First Named Inventor	P. York et al.	
SIAII		Ar	FLICANI	Group Art Unit		·-
	(use as many she	ets as	necessary)	Examiner Name	Unassigned	
Sheet 6 of 6		6	Attorney Docket Number	0113.00	/	

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	СМ	CHANG ET AL., "Precipitation of Microsize Organic Particles from Supercritical Fluids," AIChE Journal, Vol. 35, No. 11, p. 1876-1882 (November 1989).				
,	CN	MATSON ET AL., "Rapid Expasion of Supercritical Fluid Solutions: Solute Formation of Powders, Thin Films and Fibers," Ind. Eng. Chem Res., Vol. 26, p. 2298-2306 (1987).				
		STENGERS ET AL., "Carbon Dioxide at its Critical State," Chemical & Engineering News, June 10, 1968.				
			+			
			1			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.